1,000+ Opportunities
Find the right grant
Search federal, foundation, and corporate grants with AI — or browse by agency, topic, and state.
This listing may be outdated. Verify details at the official source before applying.
Find similar grantsPage exists and program is confirmed but no specific deadline information was extractable from the page content returned.
ASPIRE Award is sponsored by The Mark Foundation for Cancer Research. Supports high-risk, high-reward projects addressing key feasibility and proof-of-concept questions in cancer research.
Get a weekly digest of new grants like this
A free weekly digest of new foundation and federal funding opportunities as they're added to Granted. Unsubscribe anytime.
Or search similar grants →Extracted from the official opportunity page/RFP to help you evaluate fit faster.
ASPIRE | The Mark Foundation for Cancer Research The Mark Foundation for Cancer Research The Mark Foundation for Cancer Research The Mark Foundation for Cancer Research ASPIRE Awards support innovative ideas that have the potential to solve high-impact problems in cancer research, but may not have extensive – or any – preliminary supporting data.
ASPIRE Awards enable high-risk, high-reward projects to answer key feasibility and proof-of-concept questions and arrive at critical project inflection points in an accelerated time frame. ASPIRE Awards support work from bench to bedside, and special consideration is given to previously unaddressed questions and challenging concepts.
The scope of ASPIRE Awards includes: Basic Research : Projects that have the potential to substantially accelerate understanding of cancer disease mechanisms and pathophysiology Therapeutic Discovery and Translational Science : Projects that include initial investigations of novel concepts in cancer therapeutics and/or that seek to answer key translational science questions on the critical path to the clinic Innovative Technologies : Projects aimed at developing innovative technology solutions that are integrated with leading-edge concepts in cancer biology Clinical Research : Projects involving biomarker-rich, early-stage clinical trials and correlative studies that address fundamental questions related to the interplay of cancer therapy, intervention and/or companion diagnostics and biology Please refer to the bottom of this page to explore current and former ASPIRE awards.
Eligibility and Review Process ASPIRE Awards support research worldwide, and collaborations are within the scope of the funding mechanism Principal investigators must be independent researchers at their respective institutions Proposals may be solicited through focused Requests for Proposals (RFPs), or individual applications may be considered by invitation Applications go through a rigorous and thorough internal and external review process and are selected based on the highest level of scientific merit and potential for impact The budget and duration requested for the grant must match a realistic estimate of the cost and timeline for the proposed work, with standard awards defined as: ASPIRE I Awards for periods of 12 months or less with total budgets up to $250,000 (up to 24 months and $500,000 allowed for clinical studies) ASPIRE II Awards for periods of 36 months or less with total budgets up to $750,000 (larger amounts will be considered for clinical studies) Projects typically start as an ASPIRE I; those that successfully demonstrate feasibility or proof of concept may be invited to apply for an ASPIRE II to further develop and expand the research In unique circumstances, by invitation only, investigators may be invited to start with an ASPIRE II Award The budget limit includes both direct and indirect costs, with indirect costs not to exceed 10% of the direct costs Co-investigators are permitted Revenue sharing terms will apply Additional considerations for clinical research awards: No more the 25% of the total budget may be used to defray clinical trial costs such as research nurses, data management, IRB fees, and database development Funds will not be released until the protocol has necessary institutional approvals
According to the current listing, eligibility includes: Non-profit institutions worldwide; principal investigators must be independent researchers at their respective institutions. Confirm the full requirements in the official notice before applying.
The current listing shows up to $250,000 for 12 months (ASPIRE I) or up to $750,000 for 36 months (ASPIRE II). Verify award ceilings, matching requirements, and allowable costs in the official notice.
ASPIRE Award is funded by The Mark Foundation for Cancer Research. Verify program details on the funder's official page before applying.
This listing is flagged as international in scope. Check the official notice for country-specific restrictions before applying.
Applications go through the funder's official portal — the Apply Now link on this page goes there directly.
The Breast Cancer Research Foundation launched a $100 million venture philanthropy fund at CGI on September 22, 2026, seeded with $23 million and aiming at 20 to 30 companies. Here is what the structure actually means for investigators, for startups in the valley of death, and for every disease foundation now weighing the same move.
Read articleCDC-RFA-DP-27-0023 puts the National Breast and Cervical Cancer Early Detection Program, the National Comprehensive Cancer Control Program, and the National Program of Cancer Registries into a single competition closing February 5, 2027. Three statutorily separate eligibility pools, one application deadline, and an award count that maps onto the incumbent footprint. Here is how to read that.
Read articleCDMRP reissued the FY26 BCRP Breakthrough Award Levels 1 and 2 and the Clinical Research Extension Award on September 3, 2026, with a November 4 pre-application deadline and a November 18 full application deadline. Round one closed July 8. The arithmetic across both windows accounts for nearly the entire FY26 appropriation — which tells you what kind of second chance this is.
Read article